Outcome measures for antineutrophil cytoplasmic antibody-associated vasculitis

Current Opinion in Rheumatology

Volumn 27, Issue 1, 2015, Pages 38-44

  Tomasson, Gunnar ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

Author keywords

ANCA associated vasculitis; Disease activity; Outcome measures; Patient reported outcomes

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT;

ANCA ASSOCIATED VASCULITIS; BIRMINGHAM VASCULITIS ACTIVITY SCORE; DISEASE ACTIVITY; DRUG EFFICACY; HUMAN; OUTCOME ASSESSMENT; PLASMAPHERESIS; PSYCHOMETRY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REMISSION; REVIEW; SCORING SYSTEM; SHORT FORM 36; SYMPTOM; VASCULITIS DAMAGE INDEX; VISUAL ANALOG SCALE; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; DISEASE COURSE; IMMUNOLOGY; SEVERITY OF ILLNESS INDEX;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); SEVERITY OF ILLNESS INDEX;

EID: 84918570492     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000135     Document Type: Review

References (48)

1. Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70:488-494.
2. Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18:2180-2188.
3. Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoid dosing in the treatment of antineutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 2013; 14:1-7.
4. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87:671-678.
5. Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001; 44:912-920.
6. Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009; 68:1827-1832.
7. Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997; 40:371-380.
8. Merkel PA, Aydin SZ, Boers M, et al. The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J Rheumatol 2011; 38:1480-1486.
9. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36-44.
10. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351-361.
11. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:2461-2469.
12. Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359:2790-2803.
13. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibodyassociated vasculitis: A randomized trial. Ann Intern Med 2009; 150:670- 680.
14. Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs. azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial. J Am Med Assoc 2010; 304:2381- 2388.
15. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221-232.
16. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211-220.
17. Herlyn K, Hellmich B, Seo P, Merkel PA. Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective. Arthritis Care Res (Hoboken) 2010; 62:1639-1645.
18. Seo P, Jayne D, Luqmani R, Merkel PA. Assessment of damage in vasculitis: expert ratings of damage. Rheumatology 2009; 48:823-827.
19. Tomasson G, Davis JC, Hoffman GS, et al. Brief report: The value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener's). Arthritis Rheumatol 2014; 66:428-432.
20. Luqmani RA, Exley AR, Kitas GD, Bacon PA. Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol 1997; 11:423- 446.
21. Tomasson G, Boers M, Walsh M, et al. Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). Arthritis Care Res 2012; 64:273-279.
22. Suppiah R, Mukhtyar C, Flossmann O, et al. A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology 2011; 50:899-905.
23. Tomasson G, Lavalley M, Tanriverdi K, et al. Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis. J Rheumatol 2011; 38:1048-1054.
24. Mahr AD, Neogi T, Lavalley MP, et al. Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis. Arthritis Rheum 2008; 59:884-891.
25. Walsh M, Mukhtyar C, Mahr A, et al. Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken) 2011; 63:1055-1061.
26. DelPero MM, Chaudhry A, Rasmussen N, et al. A disease activity score for ENT involvement in granulomatosis with polyangiitis (Wegener's). Laryngoscope 2013; 123:622-628.
27. Koike K, Fukami K, Yonemoto K, et al. A new vasculitis activity score for predicting death in myeloperoxidase-antineutrophil cytoplasmic antibodyassociated vasculitis patients. Am J Nephrol 2012; 35:1-6.
28. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996; 75:17-28.
29. Whiting-O'Keefe QE, Stone JH, Hellmann DB. Validity of a vasculitis activity index for systemic necrotizing vasculitis. Arthritis Rheum 1999; 42:2365- 2371.
30. deGroot K, Gross WL, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001; 55:31-38.
31. Itabashi M, Takei T, Moriyama T, et al. Long-term damage assessment in patients with microscopic polyangiitis and renal-limited vasculitis using the Vasculitis Damage Index. Mod Rheumatol 2014; 24:112-119.
32. Koutantji M, Harrold E, Lane SE, et al. Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum 2003; 49:826-837.
33. Seo P, Min YI, Holbrook JT, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005; 52:2168-2178.
34. Merkel PA, Aydin SZ, Boers M, et al. Current status of outcome measure development in vasculitis. J Rheumatol 2014; 41:593-598.
35. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473-483.
36. Basu N, McClean A, Harper L, et al. The characterisation and determinants of quality of life in ANCA associated vasculitis. Ann Rheum Dis 2014; 73:207- 211.
37. Boers M, Kirwan JR, Wells G, et al.Developing core outcomemeasurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol 2014; 67:745-753.
38. Milman N, Boonen A, Merkel PA, Tugwell P. Mapping of the OMERACT core set for ANCA-associated vasculitis to the international classification of function, disability and health. Arthritis Care Res (Hoboken) 2014; doi: 10.1002/acr.22414. [Epub ahead of print].
39. Basu N, McClean A, Harper L, et al. Explaining fatigue in ANCA-associated vasculitis. Rheumatology (Oxford) 2013; 52:1680-1685.
40. Basu N, McClean A, Harper L, et al. Markers for work disability in antineutrophil cytoplasmic antibody-associated vasculitis. Rheumatology (Oxford) 2014; 53:953-956.
41. Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol 2010; 63:1179-1194.
42. Tucker CA, Escorpizo R, Cieza A, et al. Mapping the content of the Patient- Reported Outcomes Measurement Information System (PROMIS) using the International Classification of Functioning, Health and Disability. Qual Life Res 2014; 23:2431-2438.
43. Faurschou M, Sigaard L, Bjorner JB, Baslund B. Impaired health-related quality of life in patients treated for Wegener's granulomatosis. J Rheumatol 2010; 37:2081-2085.
44. Linde L, Sorensen J, Ostergaard M, et al. Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important? J Rheumatol 2010; 37:285- 290.
45. Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims (2009 pages). Accessed at U.S Department of Health and Human Services, Food and Drug Administration at http://www.fda.gov/downloads/Drugs/GuidaceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. [Accessed 26 July 2014].
46. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38:44-48.
47. Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005; 52:2625-2636.
48. van Gestel AM, Prevoo ML, van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39:34-40.